Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 8/20 | 0.56 |
| ▸ | THRB | P10828 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660247 | 0.95 | THRA (0.55) | THRATHRB | |
| SCHEMBL7792510 | 0.95 | THRA (0.55) | THRATHRB | |
| SCHEMBL6659916 | 0.95 | THRA (0.55) | THRATHRB | |
| SCHEMBL6661786 | 0.92 | THRB (0.53) | THRATHRBKDM4EALDH1A1LMNA | |
| SCHEMBL6659219 | 0.91 | THRA (0.56) | THRATHRB | |
| SCHEMBL7059998 | 0.90 | THRA (0.62) | THRATHRBKDM4EALDH1A1LMNA | |
| SCHEMBL6664358 | 0.87 | THRA (0.58) | THRATHRB | |
| SCHEMBL6664821 | 0.86 | THRA (0.52) | THRATHRB | |
| SCHEMBL6657667 | 0.85 | THRA (0.51) | THRATHRB | |
| SCHEMBL6739756 | 0.83 | THRA (0.62) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | claimed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | claimed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | claimed |
| EP-1157001-B1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | disclosed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | disclosed |
| US-6326398-B1 | Oxamic acids and derivatives as thyroid receptor ligands | PFIZER INC. | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, TSHR | THRA 2/4885THRB 4/4885KDM4E 4250/4885 |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, OXGR1 | THRA 2/4885THRB 4/4885KDM4E 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.